Washington, DC - "We are making America stronger, prouder, and greater than ever before." ~ President Donald J. Trump

Washington, DC - On Monday, December 30, 2019, the President signed into law:

Washington, DC - It happened on New Year’s Day,1863—two years into a bloody war that pitted the Union against the Confederacy. President Abraham Lincoln issued the Emancipation Proclamation, which declared: "on the first day of January, in the year of our Lord one thousand eight hundred and sixty-three, all persons held as slaves within any State or designated part of a State ... shall be then, thenceforward, and forever free…”

Washington, DC - The U.S. Food and Drug Administration approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Ubrelvy is not indicated for the preventive treatment of migraine. It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.

El Centro, California - Multiple agencies are investigating an officer involved shooting in El Centro.

Washington, DC - The U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. Enhertu is a human epidermal growth factor receptor 2 (HER2)-directed antibody and topoisomerase inhibitor conjugate, meaning that the drug targets the changes in HER2 that help the cancer grow, divide and spread, and is linked to a topoisomerise inhibitor, which is a chemical compound that is toxic to cancer cells.